Chemical modifications on the acyclic moiety of 3-(2-hydroxyethoxy)-1-alkoxypropyl nucleobases. 2. Differentiation and growth inhibition in rhabdorayosarcoma cells after exposure to a novel 5-fluorouracil acyclonucleoside

Tetrahedron

Volumn 53, Issue 21, 1997, Pages 7319-7334

  Gómez, Jose A ^a   Campos, Joaquín ^a   Marchal, Juan A ^b   Trujillo, María A ^a   Melguizo, Consolación ^c   Prados, José ^c   Gallo, Miguel A ^a   Aránega, Antonia ^b   Espinosa, Antonio ^a  

^a Facultad de Medicina   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c Departamento de Ciencias de la Salud y Psicología Clínica   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACYCLIC NUCLEOSIDE; ANTINEOPLASTIC AGENT; FLUOROURACIL; FLUOROURACIL DERIVATIVE;

ARTICLE; CELL DIFFERENTIATION; CELL LINE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PRIORITY JOURNAL; RHABDOMYOSARCOMA;

EID: 0030914128     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(97)00415-8     Document Type: Article

References (41)

1. For part 1, see Campos, J.; Pineda, M. J.; Gómez, J. A.; Entrena, A.; Trujillo, M. A.; Gallo, M. A.; Espinosa, A. Tetrahedron, 1996, 52, 8907.
2. Schaeffer, H. J.; Beauchamp, L.; De Miranda, P.; Elion, G. B.; Bauer, D. J.; Collins, P. Nature, 1978, 272, 583.
3. Harnden, M. R.; Bailey, S; Shanks, C. T. Eur. Pat. Appl. EP 49,144 (C1 COZD239/54), 1982; via Chem. Abstr., 1982, 97, 72384d.
4. Ochi, K.; Miyamoto, K.; Miura, Y.; Mitsui, H.; Matsunaga, I.; Shindo, M. Chem. Pharm. Bull., 1985, 33, 1703.
5. Universidad de Granada, Eur. Pat. Appl. WO 91 17,147 (Cl. CO7D239/54); via Chem. Abstr. 1992, 117, 49156d.
6. D'Amore E. S. G.; Tollot, M.; Stracca-Panca, V.; Menegon, A.; Mell, S.; Ninfo, V. Modern Pathol., 1994, 7, 69.
7. Crouch, G. D.; Kalebic, T.; Tsokos, M.; Helman, L. J. Exp. Cell. Res., 1993, 204, 210.
8. Melguizo, C.; Prados, J.; Fernández, J. E.; Vélez, C.; Álvarez, L.; Aránega, A. Cell Mol. Biol., 1994, 40, 137.
9. Shimada, H.; Newton, W. A.; Soule, E. H.; Beltangady, M. S.; Maurerx M. S. Cancer, 1987, 59, 459.
10. Altmannsberger, M.; Weber, K.; Droste, R.; Osborn, M. Am. J. Pathol., 1985, 118, 85.
11. Vélez, C.; Muros, M. A.; Aránega A. E.; Fernández, J. E.; González, F. J.; Álvarez, L.; Aránega, A. Acta Anat., 1990, 139, 226.
12. Prados, J.; Melguizo, C.; Fernández, J. E.; Aránega, A. E., Álvarez, L.; Aránega, A. Cell. Mol. Biol., 1993, 39, 525.
13. Farquhar, D.; Chen, R.; Khan, S. J. Med. Chem., 1995, 38, 488.
14. Fluoropyrimidines are amongst the few options in the chemotherapeutic treatment of colorectal cancers.
15. Braña, M. F.; Castellano, J. M.; Morán, M.; Pérez de Vega, M. J.; Romerdahl, C. A.; Quian, X-D.; Bousquet, P.; Emling, F.; Schlick, E.; Keilhauer, G. Anticancer Drug Res., 1993, 8, 257.
16. Espinosa, A.; Gallo, M. A.; Campos, J. Bull. Soc. Chim. Fr., 1983, 11, 269.
17. Hall, R. H.; Stern, E. S. J. Chem. Soc., 1952, 4083.
18. 3.
19. 7-isomer using trimethylsilyl trifluoromethanesulfonate and tin (IV) chloride, respectively, see: Zaitseva, G. V.; Sivets, G. G.; Kazimierczuk, Z.; Vilpo, J. A.; Mikhailopulo, I. A. Biorg. & Med. Chem. Lett., 1995, 5, 2999.
20. Chenon, M.-T.; Pugmire, R. J.; Grant, D. M.; Panzica, R. P.; Townsend, L. B., J. Am. Chem. Soc., 1975, 97, 4627.
21. March, J., Advanced Organic Chemistry, John Wiley & Sons, New York, 1992; pp. 308-312.
22. Espinosa, A.; Gallo, M. A.; Campos, J.; Gómez, J. A. Synlett, 1995, 11, 1119.
23. Espinosa, A.; Gallo, M. A.; Campos, J., An. Quim., 1982, 78C, 232.
24. Taber, D. F.; Amedio, J. C. Jr.; Jung, K.-Y. J. Org. Chem., 1987, 52, 5621.
25. 5, see Onodera, K.; Hirano, S.; Kashimura, N. J. Am. Chem. Soc., 1965, 87, 4651.
26. R=3.03 min, purity=93%. Such a sample was used without further purification in the next step.
27. Corey, E. J.; Suggs, J. W. Tetrahedron Lett., 1975, 2647.
28. (a) Coates, W. M.; Corrigan, J. R.; Chem. Ind. (London), 1969, 1594;
29. (b) Corey, E. J.; Schmidt, G. Tetrahedron Lett., 1979, 399;
30. (c) Czernecki, S.; Georgoulis, C.; Stevens, C. L.; Vijayakumaran, K. Tetrahedron Lett., 1985, 26, 1699.
31. Lifshitz, E.; Goldfarb, D.; Vega, S.; Luz, Z; Zimmermann, H. J. Am. Chem. Soc., 1987, 109, 7281.
32. (a) Bowden, K.; Heilbron, I. M. ; Jones, E. R. H.; Weedon, B. C. L. J. Chem. Soc. 1946, 39;
33. (b) Bowers, A.; Halsall, T. G.; Jones, E. R. H.; Lemin, A. J. J. Chem. Soc. 1953, 2548.
34. Pizzorno, G.; Sun, Z.; Handschumacher, R. E. Biochem. Pharmacol., 1995, 49, 553.
35. Briefly, through FACScan we endeavour to monitor the cellular components by means of specific monoclonal antibodies for such components. This technique lies in the measurement of both the scattered laser light by cells and the emitted fluorescence by the cells labelled by a fluorescent antibody directed towards such a cellular component. Significance was determined by comparison of the means with Student's test. All differences were significant at p < 0.001.
36. Aránega, A.; Marchal, J. A.; Melguizo, C.; Prados, J.; Aránega, A. E.; Vélez, C.; Fernández, J. E.; Arena, N.; Álvarez, L. Cell. Mol. Biol., 1996, 42, 1219.
37. (a) Lesuffleur, T.; Kornowski, A.; Luccioni, C.; Muleris, M.; Barbat, A.; Beaumatin, J.; Dussaulx, E.; Dutrillaux, B.; Zweibaum, A. Int. J. Cancer, 1991, 49, 721;
38. (b) Lesuffleur, T.; Kornowski, A.; Augeron, C.; Dussaulx, E.; Barbat, A.; Laboisse, C.; Zweibum, A. Int. J. Cancer, 1991,49, 731.
39. (a) Lotan, R.; Francis, G. E.; Freeman, C. S.; Waxman, S. Cancer Res. 1990, 50, 3453;
40. (b) Zupi, G.; Marangolo, M.; Arancia, G.; Greco, C.; Laudonio, N.; Iosi, F.; Formisano, G.; Malorni, W. Cancer Res. 1988, 48, 6193;
41. (c) Waxman, S.; Huang, Y.; Scher, B. M.; Scher, M. Biomed. Pharmacother. 1992, 46, 183.